


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



# 華控康泰集團有限公司

## Kontafarma China Holdings Limited

*(Incorporated in the Cayman Islands with limited liability)*

(Stock Code: 1312)

### ANNOUNCEMENT PURSUANT TO RULES 13.51B(2) AND 13.51(2) OF THE LISTING RULES

This announcement is made by Kontafarma China Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.51B(2) and 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

Reference is made to the announcement of the Company dated 19 September 2023 (the “**Announcement**”) in relation to the notice of criticism issued by the Shenzhen Stock Exchange (the “**SZSE**”) against, among others, Shenzhen Huakong Seg Co., Ltd.\* (深圳華控賽格股份有限公司) (“**Huakong Seg**”), a company listed on the SZSE (stock code: 000068), and Mr. Chai Hongjie (“**Mr. Chai**”), an executive director of the Company, who was the general manager of Huakong Seg at the relevant time (the “**Decision**”). As disclosed in the Announcement, the Decision was made based on the fact that the estimated net profit disclosed in the 2022 annual results forecast of Huakong Seg was significantly different from the audited net profit disclosed in its 2022 annual report and there has been a change in nature of profit and loss (the “**Incident**”). Please refer to the Announcement for details of the Decision granted by the SZSE in relation to the Incident.

It came to the knowledge of the Company recently that on 7 November 2023, Huakong Seg received a warning letter (No. [2023]202) (the “**Warning Letter**”) issued by the Shenzhen Regulatory Bureau of the China Securities Regulatory Commission (the “**CSRC**”) against, among others, Huakong Seg and Mr. Chai.

The CSRC mainly stated in the Warning Letter that on 29 April 2023, Huakong Seg disclosed the revised 2022 annual results forecast announcement, which substantially revised its 2022 annual results forecast. Upon investigation, it was found that Huakong Seg was not prudent in the recognition of relevant investment income, resulting in a significant deviation in the relevant financial data set out in the 2022 annual results forecast disclosed by Huakong Seg on 30 January 2023. The foregoing was in breach of the relevant laws in the People’s Republic of China (the “**PRC**”), and Mr. Chai and other responsible personnel of Huakong Seg have the primary responsibility. Accordingly, the CSRC issued the Warning Letter against, among others, Huakong Seg and Mr. Chai.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company (other than Mr. Chai) understands that the relevant incident on which the Warning Letter is based is identical to the Incident that was described in the Announcement previously published by the Company. The Board has assessed the entire incident and understands that the CSRC has not indicated that the Incident involves any dishonesty, fraud or integrity issue on the part of Mr. Chai. In addition, Mr. Chai has not been ordered by the CSRC to be prohibited from acting as a director of any company listed in the PRC as a result of the Incident. Having considered the implications of the Warning Letter as well as the character, past compliance track record, experience and integrity of Mr. Chai as a whole, the Board (with Mr. Chai having abstained from making any consideration and decision) is of the view that the Incident has not impaired the suitability of Mr. Chai for acting as a Director and Mr. Chai is able to continue to perform his duties as a Director.

The Warning Letter is not made against any members of the Group and the Board is of the view that there is no material adverse impact on the business and/or operation of any members of the Group as a result of the Warning Letter.

By order of the Board  
**Kontafarma China Holdings Limited**  
**Bai Pingyan**  
*Chairman*

Hong Kong, 12 December 2023

*As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Bai Pingyan (Chairman), Mr. Chai Hongjie, Mr. Huang Yu (President) and Mr. Jiang Chaowen (Chief Executive Officer); and three independent non-executive Directors, namely Mr. Chan Sze Chung, Mr. Zhang Ruibin and Mr. Zhang Junxi Jack.*

\* *For identification purposes only*